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Abstract
Background: Vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI) is generally associated with the
delayed administration of adequate antibiotics. The identification of risk factors and outcomes of VRE BSI is
necessary for establishing strategies for managing neutropenic fever in patients with hematological malignancies.
Methods: We retrospectively analysed consecutive cases of enterococcal BSI in patients with neutropenia after
chemotherapy or stem cell transplantation between July 2009 and December 2011 at a single center.
Results: During the 30-month period, among 1,587 neutropenic patients, the incidence rate of enterococcal BSI
was 1.76 cases per 1,000 person-days. Of the 91 enterococcal BSIs, there were 24 cases of VRE. VRE BSI was
associated with E. faecium infection (P < .001), prolonged hospitalization (P = .025) and delayed administration
(≥48 hours after the febrile episode) of adequate antibiotics (P = .002). The attributable mortality was 17% and 9%
for VRE and vancomycin-susceptible Enterococcus (VSE), respectively (P = .447). The 30-day crude mortality was 27%
and 23% for VRE and VSE, respectively (OR 1.38, 95% CI 0.53–3.59; P = .059). Only SAPS-II was an independent
predictive factor for death (adjusted OR 1.12, 95% CI 1.08–1.17; P < .001).
Conclusions: In conclusion, vancomycin resistance showed some trend towards increasing 30-day mortality, but is
not statistically significant despite the delayed use of adequate antibiotics (≥48 hours). Only underlying severity of
medical condition predicts poor outcome in a relatively homogeneous group of neutropenic patients.
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Background
Enterococcal bloodstream infections (BSI) have been in-
creasing in hospitalized patients since the 1990s [1,2].
Enterococci are normal intestinal flora of humans, but
usually cause infections when immunity of the host is
compromised [3]. At our Blood and Marrow Transplan-
tation Center, Enterococcus has emerged as the third most
common pathogen, constituting 14.0% of all BSIs, and
vancomycin resistant Enterococcus (VRE) was responsible
for 20.6% of proven enterococcal BSIs [4]. There are
several studies on outcomes after administration of
newer antimicrobial agents such as linezolid, dapto-
mycin, quinupristin-dalfopristin or tigecycline [5,6]. But
VRE BSI is still a major concern, because of the limited
therapeutic options available and higher mortality subse-
quent to infection [7,8].
It has been demonstrated that vancomycin resistance
increases mortality in patients with enterococcal BSI
[1,9-14]; however, controversy remains [5,15-19]. Con-
flicting results on the clinical implications of vanco-
mycin resistance may have been due to the varied
severity of the underlying illness in patients with VRE
BSI. Previous meta-analysis concluded that vancomycin
resistance is independently associated with increased
mortality in enterococcal BSI [1]. However, only a subset
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of the studies involved in the meta-analysis examined
immunocompromised individuals [13,14].
Whether vancomycin resistance increases mortality in
patients with enterococcal BSI could be one of the import-
ant considerations in determining empirical therapeutic
approach, especially in the setting of chemotherapy-
induced reversible neutropenia. This study examined the
risk factors and outcomes of VRE BSI as compared with
vancomycin-susceptible Enterococcus (VSE) BSI, and the
factors associated with mortality in a relatively homoge-
neous group of patients with neutropenia after chemo-
therapy or stem cell transplantation (SCT) for underlying
hematologic diseases.
Methods
Study design and clinical setting
We retrospectively reviewed all consecutive episodes of
enterococcal BSIs in adult patients with neutropenic
fever from July 2009 to December 2011 at the Catholic
Blood and Marrow Transplantation Center, Seoul St.
Mary’s Hospital. Our hospital is a 1,200-bed, university-
affiliated, tertiary-care center in Seoul, South Korea. The
Catholic Blood and Marrow Transplantation Center per-
forms over 350 SCTs annually.
Eligible patients included those with hematological
malignancies, who experienced neutropenic fever during
chemotherapy or SCT, who were older than 18 years of
age, and were documented to be blood culture positive
for Enterococcus species. Enterococcal BSI cases were
obtained from a computerized microbiology database.
We collected data targeted to positive blood culture re-
sults from chemotherapy ward and SCT ward. In cases
with persistent BSI, we analysed the first episode. If
cases met the definition of separate BSI, each infection
was considered individually. Concomitant VRE and VSE
BSI were excluded. Even in cases with neutropenic fever
and documented enterococcal BSI, patients who had not
previously received treatment for hematological malig-
nancies, such as anti-cancer chemotherapy or SCT, were
excluded.
The data obtained for each patient included age, sex,
underlying diseases, absolute neutrophil count (ANC) at
the onset of fever, severity and duration of neutropenia,
severity of illness (Simplified Acute Physiology Score,
SAPS II) and Charlson’s comorbidity index at the onset
of BSI, length of hospital stay, stay in intensive care unit
(ICU) before the onset of BSI, septic shock, the presence
of previously documented rectal VRE colonization, or-
ganisms isolated from blood and antimicrobial suscep-
tibility, antibiotics administered, and survival 7 and 30
days after the onset of BSI.
Blood for cultures was sampled using sterile tech-
niques, with one set from peripheral vein puncture and
another set simultaneously from a central venous catheter.
Each 10~15 mL of blood was inoculated into aerobic and
anaerobic bottles (BD BACTEC™ Plus Aerobic/F, Lytic/10
Anaerobic/F Culture Vials, Becton Dickinson, Sparks,
MD, USA), which were immediately transported to
the clinical laboratory. Antibiotic susceptibility testing
was performed with an automatic system (Vitek-2,
bioMérieux, Hazelwood, MO, USA). E. faecalis clin-
ical isolates are almost always susceptible to ampicil-
lin; hence, ampicillin sensitivity of E. faecalis was not
tested in our study. Polymerase chain reaction (PCR)
test to look for van A, B, C genes was not performed
routinely.
At our center, during the chemotherapy or SCT, oral
ciprofloxacin (500 mg twice a day) is used as routine
prophylaxis. The initial empirical treatment of neutro-
penic fever in hematological malignancy patients is to
use anti-pseudomonal cephalosporin (cefepime or cef-
tazidime) and/or an aminoglycoside (isepamicin), ex-
cluding the initial use of glycopeptides. The use of
glycopeptides as empirical antimicrobial therapy is re-
commended if the patient’s blood cultures are positive
for Gram-positive bacteria, a catheter-related infection is
suspected, there is a history of MRSA infection, the
patient has severe sepsis or shock pending the results of
cultures, the patient has severe mucositis, or the patient
has skin or soft tissue infection. If Gram-positive bac-
teremia persists for 2 or 3 days after adding glycopep-
tides, we consider anti-VRE therapy before receiving the
final microbiology results [20,21].
Rectal VRE surveillance is not routinely performed in
patients undergoing chemotherapy or SCT according to
ASBMT guidelines [22]. For cases of previous VRE in-
fection or hospitalization in the ICU, rectal swabs for
VRE surveillance are performed. All VRE-colonized or -
infected persons are placed under contact precautions
for nosocomial infection control until they have three
consecutive negative results.
The Institutional Review Board of Seoul St. Mary’s
hospital approved the research protocol with a waiver of
informed consent (KC12RISI0314).
Definitions
Enterococcal BSI was defined as isolation of Entero-
coccus species in two or more blood culture results
[1,8,13,15,17]. Enterococcal BSI occurring 60 or more
days after a previous initial episode was considered a
separate episode [8,12]. Neutropenia was defined as
an ANC <500/mm3, or <1000/mm3 with predicted falls
to <500/mm3 within 2~3 days. Severe neutropenia was
defined as an ANC <100/mm3 [20,23]. Fever was defined
as an increase in body temperature to over 38.0°C using
a tympanic thermometer or to over 37.5°C using an axil-
lary thermometer [20]. The length of hospitalization was
defined as the number of days from hospital admission
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to the development of clinically significant enterococcal
bacteremia. Intermediate susceptibility was classified as
‘non-susceptible’. Clinical outcomes were classified as
‘improvement’ indicating resolution of the signs of sys-
temic inflammatory response syndrome (SIRS), ‘failure’
for any sustained signs of infection or death [24]. Micro-
biologic outcomes were classified as ‘eradication’ or ‘per-
sistence’ [11]. When any follow-up blood culture result
was positive for Enterococcus species, the case was
considered as ‘persistence’. When 7-day microbiologic
outcome showed ‘persistence’, it considered as ‘microbio-
logic failure’ at 7 day after the febrile episode. Mortality
was considered attributable to the Enterococcus if the pa-
tient died within 7 days of the BSI and no other cause
could be identified. Crude mortality was defined as mor-
tality that occurred within the month that followed a
BSI episode [25]. Empirical antimicrobial therapy was
considered to be appropriate when at least one active
antimicrobial agent susceptible to the organism by
in vitro test was administered [26]. The length of de-
lay until adequate antibiotics treatment was defined
as the interval between the onset of fever and the
time that antibiotics to which the organism was sus-
ceptible were administered. Delayed administration of
adequate antibiotics was defined when the length of
the delay was 48 hours or more [12].
Statistical analysis
To identify factors associated with the development of
VRE BSI, chi-square analysis or Fisher’s exact test was
used to compare categorical variables, and a Student’s
t-test or Mann–Whitney U test was used to compare
continuous variables. In order to identify factors asso-
ciated with mortality, Cox proportional hazard model
with backward method was used to control for the ef-
fects of confounding variables. Kaplan-Meier survival
curves were used to analyse the mortality trends, and the
results were compared using the log-rank test. SAPS-II
score at the onset of febrile episode was analysed by
using receiver operating characteristic (ROC) curve.
For measures of association, a 2-tailed P < .05 was
considered to be significant. Statistical analysis were
performed using SAS software ver. 8.2 (SAS Institute
Inc., Cary, NC, USA).
Results
During the 30-month period, among a total of 2,028 pa-
tients admitted with hematological malignancies, 1,587
developed neutropenia during chemotherapy or SCT,
and 91 episodes of enterococcal BSIs were identified. Of
these infectious episodes, 24 (26.4%) were VRE BSIs.
The incidence rate of enterococcal BSI in neutropenic
patients who underwent chemotherapy or SCT was 1.76
cases per 1,000 person-days. There were 2 cases of
concurrent VRE and VSE bacteremia. It was excluded
because of the interpretative problem. A review of
monthly incidence rates of enterococcal BSIs showed
that no outbreaks occurred during this study period.
The baseline characteristics are shown in Table 1.
There were no differences in age, sex, SAPS-II and
Charlson’s comorbidity index, and the duration and se-
verity of neutropenia between VSE and VRE BSI groups.
VRE BSI was associated with E. faecium infection
(P < .001) and prolonged hospitalization (P = .025).
All of the patients in this study had a central venous
catheter for their chemotherapy or SCT, which was
Hickman catheter or chemoport. Delayed administra-
tion of adequate antibiotics (more than 48 hours after
the febrile episode) was more common in VRE BSI
than in the VSE BSI group (P = .002). The median interval
from the onset of the febrile episode to the administration
of adequate antibiotics was 1.4 (range <1 ~ 5) days in the
VSE BSI group and 2.8 (range <1 ~ 5) days in the VRE BSI
group. Enterococcal BSI developed a median of 14 days
after the onset of neutropenia. In the VSE BSI group,
61.2% of the patients had acute myeloid leukaemia
(AML), while acute lymphoblastic leukaemia (ALL)
was the major underlying disease (54.2%) in the VRE
BSI group (P = .046).
The outcomes are shown in Table 2. The 7-day clinical
treatment failure rate was 50.0% and 26.9% in VRE and
VSE BSI, respectively (P = .040), while microbiologic
failure at 7 days after the onset of BSI did not differ sig-
nificantly (16.7% and 11.9%, P = .499). Despite the de-
layed administration of adequate antibiotics and delayed
resolution of the signs of SIRS in the VRE BSI group, the
attributable mortality was 16.7% for VRE and 9.0% for
VSE BSI (P = .447). The 30-day crude mortality was
27.3% for VRE and 22.7% for VSE (hazard ratio [HR]
1.38, 95% confidence interval [CI] 0.53–3.59; P = .059).
Kaplan–Meier curves comparing patient survival are
shown in Figure 1. In the Cox proportional hazard ana-
lysis, with the satisfaction of the assumption of ‘propor-
tional hazards’, only SAPS-II at the onset of BSI proved
to be an independent risk factor for death (adjusted HR
1.12, 95% CI 1.08–1.17; P < .001) (Table 3). Analysing by
ROC curve, SAPS-II at the onset of febrile episode is a
good predictive factor for 30-day crude mortality with
area under the curve (AUC) value of 0.817 (P <.001).
With a cut-off value of 42.5, the sensitivity and specifi-
city for 30-day crude mortality was 0.810 and 0.791,
respectively.
Table 4 shows the susceptibility patterns according to
Enterococcus species. Of the 91 isolates, 66 (72.5%) were
E. faecium, 23 (25.3%) were E. faecalis, and 2 (2.2%)
were E. gallinarum. One-third of the E. faecium isolates
(22 of 66) were resistant to vancomycin. Both E. gal-
linarum isolates were resistant to vancomycin. Of the
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E. faecium isolates, all were resistant to ampicillin, 75.8%
(50 of 66) showed high-level resistance to gentamicin, and
all were susceptible to quinupristin-dalfopristin. Two E.
faecium isolates were not susceptible to linezolid: one iso-
late showed intermediate susceptibility and one showed
resistance; in both, the MIC changed to susceptible when
the blood cultures were repeated. Among the E. faecalis
isolates, 69.6% (16 of 23) were resistant to high-level gen-
tamicin, and all isolates were susceptible to glycopeptides
and linezolid. For tigecycline, 97.0% (64 of 66) of the E.
faecium and 95.7% (22 of 23) of the E. faecalis isolates
were susceptible.
Among the 24 VRE BSI patients, rectal swabs for VRE
were performed in 20 patients, 90% (18 of 20) of whom
Table 1 Descriptive baseline characteristics of patients with enterococcal bloodstream infections
VSE BSI (n=67) VRE BSI (n=24) p-value
Age, years 48.0±14.0 44.9±14.5 0.356
Male sex 41 (61.2) 10 (41.7) 0.098
Underlying hematologic diseases 0.046
AML 41 (61.2) 10 (41.7) 0.098
ALL 18 (26.9) 13 (54.2) 0.015
Othersa 8 (11.9) 1 (4.2) 0.436
Treatment for underlying diseases 0.861
Chemotherapy 56 (83.6) 20 (83.3) >0.999
Allogeneic SCT 9 (13.4) 4 (16.7) 0.738
Autologous SCT 2 (3.0) 0 (0) >0.999
Enterococcal species <0.001
E. faecium 44 (65.7) 22 (91.7) 0.016
E. faecalis 23 (34.3) 0 (0.0) <0.001
E. gallinarum 0 (0.0) 2 (8.3) 0.067
SAPS II at the onset of BSI 39 (28–95) 41 (31–74) 0.336
Charlson’s comorbidity index 2 (0–4) 2 (0–4) 0.644
ICU care 16 (23.9) 7 (29.2) 0.609
Septic shock 8 (11.9) 2 (8.3) >0.999
Length of hospitalization, day 22 (13–44) 26 (17–77) 0.025
Duration of neutropenia before BSI, day 14 (0–156) 15 (6–27) 0.908
Severity of neutropenia 0.112
ANC <500/mm3 2 (3.0) 3 (12.5)
ANC <100/mm3 65 (97.0) 21 (87.5)
Administration of adequate antibiotics 0.002
≤48 hours after febrile episode 50 (75.8) 10 (41.7)
>48 hours after febrile episode 16 (24.2) 14 (58.3)
Data are presented as n (%), mean±SD or median (range). Abbreviations: ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, ANC absolute neutrophil
count, BSI bloodstream infection, ICU intensive care unit, SAPS II Simplified Acute Physiology Score, SCT stem cell transplantation, VRE, vancomycin-resistant
enterococci, VSE vancomycin-susceptible enterococci. aMyelodysplastic syndrome (n=2), multiple myeloma (n=1), aplastic anemia (n=3), lymphoma (n=2) and
hemophagocytic lymphohistiocytosis (n=1).
Table 2 Outcomes of enterococcal bloodstream infection in the VSE and VRE BSI groups
Total (n=91) VSE BSI (n=67) VRE BSI (n=24) P-value
7-day clinical treatment failure 30 (33.0) 18 (26.9) 12 (50.0) 0.040
7-day microbiologic failure 12 (13.2) 8 (11.9) 4 (16.7) 0.499
Mortality
Attributable mortality 10 (11.0) 6 (9.0) 4 (16.7) 0.447
Crude mortality 21 (23.9) 15 (22.7) 6 (27.3) 0.059
Data are presented as n (%). Abbreviations: BSI bloodstream infection, VRE vancomycin-resistant enterococci, VSE vancomycin-susceptible enterococci.
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were positive. Results of rectal swabs done previous to
diagnosis of VRE BSI were only available in 9 patients, 2
of whom (22.2%) showed a positive result, indicating
rectal VRE colonization prior to BSI.
We conducted a subgroup analysis of the 66 E. fae-
cium BSIs to eliminate the differences that may have re-
sulted from inclusion of multiple enterococcal species in
the overall study cohort. This analysis showed concor-
dant mortality results between vancomycin-susceptible
and vancomycin-resistant E. faecium.
Discussion
This study examined the impact of vancomycin resis-
tance on mortality in neutropenic patients with ente-
rococcal BSI. The results in this study indicate that
vancomycin resistance does not affect the 7-day and
30-day mortalities in a relatively homogeneous group of
patients. A meta-analysis estimated that VRE BSI is as-
sociated with a 2.52-fold increased mortality [1]. How-
ever, it is still controversial whether VRE BSI results in
higher mortality than VSE BSI in neutropenic patients
[12,18,19]. In general, the clinical impact of vancomycin
resistance is thought to be more pronounced in im-
munocompromised patients. Several reports indicate
that hematological malignancy is a risk factor for VRE
infections [7,8]. However, the use of antibiotics and se-
verity of underlying disease should be considered in any
outcome analysis because outcomes may be affected by
variables such as antibiotic treatment strategies during
treatment for neutropenic fever.
There was a significant delay in effective anti-VRE
therapy for over 48 hours, and the maximum delay was
5 days based on the culture results in the VRE BSI
group. However, despite the delayed administration of
adequate antibiotics and delayed improvement of clinical
signs of SIRS in the VRE group, the 7- and 30-day mor-
tality rates did not differ between the two groups. One
report indicates that VRE is a dominant pathogen before
engraftment in the setting of SCT, emphasizing the poten-
tial utility of the empirical treatment of Gram-positive
Figure 1 Kaplan-Meier curves for survival. Kaplan–Meier curves
for survival during episodes of bloodstream infections (BSIs) with
vancomycin-resistant enterococci (VRE) versus vancomycin-susceptible
enterococci (VSE) (Log rank test, P = .509).
Table 3 Factors associated with 30-day mortality in





Age, years 1.03 (0.99–1.06)
Male sex 1.00 (0.62–1.62)
Vancomycin resistance 1.38 (0.53–3.59) 0.75 (0.24–2.36)
SAPS II at the onset of BSI
(per 1 point)





Treatment for underlying diseases
Chemotherapy 1.00
SCT 1.33 (0.72–2.47)
Length of hospitalization, day 1.05 (1.02–1.09) 1.00 (0.98–1.02)





ANC (<100/mm3) 0.43 (0.10–1.86)
Delayed administration of adequate
antibiotics (> 48 hours)
0.78 (0.30–2.04)
Abbreviations: ALL acute lymphoblastic leukemia, AML acute myeloid leukemia,
ANC absolute neutrophil count, BSI bloodstream infection, CI Confidence
interval, HR Hazard ratio, ICU intensive care unit, SAPS II Simplified Acute
Physiology Score, SCT stem cell transplantation, OR Odds ratio, VRE
vancomycin-resistant enterococci, VSE vancomycin-susceptible enterococci.








Ampicillin 0 (0) - 2 (100)
High level gentamicin synergy 16 (24.24) 7 (30.43) 2 (100)
Vancomycin 44 (66.67) 23 (100) 0 (0)
Teicoplanin 47 (71.21) 23 (100) 2 (100)
Linezolid 64 (96.97) 23 (100) 2 (100)
Quinupristin-dalfopristin 66 (100) 0 (0) 0 (0)
Tigecycline 64 (98.46) 22 (95.65) 2(100)
Data are presented as n (%).
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organisms in the pre-engraftment period in febrile SCT
patients [14]. But, there are many considerations to decide
empirical antibiotics including incidence, risk and out-
comes. In addition, virulence of the pathogen, break-
through infection, overtreatment and emerging resistance
are also important in decision making. Our results suggest
that clinicians need to be careful to add anti-VRE therapy
empirically or pre-emptively before obtaining the final
microbiology results. Current antibiotics strategy of ad-
ding glycopeptides in febrile neutropenic patients with
presumptive Gram-positive bacteremia might be sufficient
on the premise that treatment must be individualized.
Mortality related to VRE BSI has been reported to vary
from 4~80% [9-18,27,28]. As mentioned above, such a
broad range may stem from the diverse underlying con-
ditions and different antimicrobial strategies. Recently,
Vydra et al. reported that mortality 30 days after entero-
coccal infection was 38% for both VRE and VSE BSI
cases in SCT patients and non-relapse mortality 1 year
after transplant was 53% and 33% for VRE and VSE BSI
cases respectively [27]. These results are similar to ours,
as the 30-day mortality showed no difference between
the two groups, while the 1-year mortality after SCT in
VRE infections may reflect the severity of the underlying
medical condition, rather than the poor outcome por-
tended by vancomycin resistance itself. Interestingly,
higher vancomycin resistance rate was reported in their
cohort, with 66% VRE BSI among enterococcal BSI
compared to ours. In their cohort, standard antibiotic
therapy included ceftazidime, vancomycin, and often
tobramycin until results of cultures were obtained, and
such a strategy may have influenced the vancomycin re-
sistance rate in enterococcal BSIs.
Possible causes that our results showed no difference
between the VSE and VRE BSI group include the fol-
lowing; first, the known higher mortality in the VRE
BSI group may be due to host factors, rather than a
pathogen-related factor [5,19]. Our study population was
a relatively homogeneous group that showed neutro-
penia after treatment for hematological malignancies.
The statistically equivalent initial SAPS II at the onset of
BSI may have contributed to the similar outcome of the
two groups. Second, the differences in virulence amongst
the enterococcal species can be considered. E. faecium is
more frequently associated with vancomycin resistance
than is E. faecalis. Some studies have examined animal
models, with one study using an intestinal model of
Caenorhabditis elegans reporting that low inoculums of
E. faecalis grow to a high titer in the C. elegans intestine,
resulting in persistent infection and death, whereas a
high ingested titer of E. faecium also accumulates in the
nematode gut, but did not cause death [29]. Another ani-
mal study reported that in an intraperitoneal mouse mo-
del, a greater inoculum size was required with E. faecium
than with E. faecalis strains [30]. Based on these results,
the higher virulence of E. faecalis species may have im-
pacted upon the similar mortality shown in the VSE and
VRE groups.
Interestingly, a difference in the vancomycin resistance
rate between myeloid and lymphoid malignancy was
observed, with more patients with ALL in the VRE
group. There are some reports that neutrophils play a
critical role in the pathogenesis of enterococcal infec-
tions [31,32]. However, the immune responses to En-
terococci are poorly understood. Our finding is not
consistent with the results of Worth et al., who iden-
tified an underlying diagnosis of AML as a risk factor
for VRE [33]. Theirs was a case–control study between
patients with and without VRE infection, not between
VRE- and VSE-infected groups. Moreover, there was an
outbreak of VRE infection in the hematology unit, and
empirical antibiotic therapy was modified during the study
period. These factors may explain discrepancies found be-
tween their results and ours, although further studies are
needed.
According to CDC criteria for nosocomial infection,
enterococcal BSI was defined as any blood culture gro-
wing enterococcus species [34]. But diverse definitions
have been used for each study (≥1 or 2 blood culture re-
sults), which may result in selection bias. Therefore, to
use a strict BSI definition, we included cases with two or
more positive blood cultures of enterococcal species
[1,8]. We also included only BSI cases that occurred dur-
ing neutropenia related to their treatment with exclusion
of cases undergone palliative care. This study design
made our study population as a relatively homogeneous
group with reversible neutropenia. And we calculated
the incidence rate of enterococcal BSI considering hos-
pital stay. In addition, a subgroup analysis was per-
formed for E. faecium BSI, and gave concordant results.
Our investigations have important implications for cli-
nical practice.
Nevertheless, our study has some limitations. First, it
was a retrospective study. The retrospective design made
it difficult to evaluate the duration of bacteremia and
gastrointestinal disease. Second, VRE surveillance is not
routinely performed in our center, data for VRE colo-
nization would be insufficient [22,35]. Third, we selected
the definition of enterococcal BSI with 2 or more blood
culture positivity, the incidence rate might be affected.
Fourth, it had a limitation stemming from its sample
size. Based on a previous meta-analysis [1], we assumed
a crude mortality for the VSE BSI group of 20% and an
odds ratio (OR) for vancomycin resistance on mortality
of 2.52. Based on these assumptions, the statistical po-
wer of this study to detect a significant difference in
mortality is a power of 40% in a 2-sided test with a pro-
bability of 0.05. However the mortality data and the OR
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to calculate the sample sizes are not for an immunocom-
promised population and may include confounding ef-
fects of underlying diseases and severity.
Conclusions
In summary, our data suggest that enterococcal BSI due
to vancomycin-resistant species in patients with hema-
tological malignancies tends to occur after a long period
of hospitalization. SAPS-II predicts poor outcome,
reflecting patient age and the severity of illness. By con-
trast, severe neutropenia and vancomycin resistance
itself did not appear to affect the fatality rate. The attrib-
utable and crude mortality were not different between
VRE and VSE BSI groups despite the delayed use of ad-
equate antibiotics in a relatively homogeneous immuno-
compromised group. Further prospective controlled
studies are needed.
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